Skip to main content
. 2019 Dec;103(4):388–394. doi: 10.1016/j.jhin.2019.06.003

Table I.

Characteristics of 705 Clostridium difficile episodes with ribotyped isolates

Ribotype RT220
Total (%)
RT002 + RT015
Total (%)
All other ribotypes
Total (%)
P-valueb
Demographic data
No. of C. difficile episodes with ribotyped isolates (N=705) 23 (3.3) 159 (22.6) 523 (74.2)
Total no. of unique patients (N=672) 21 (91.3) 153 (96.2) 498 (95.2) 0.57
Age range of C. difficile episodes (years)
<65 4 (17.4) 45 (28) 165 (31.5) 0.17
65–79 13 (56.5) 54 (33.9) 168 (32.1)
>80 6 (26.1) 60 (37.7) 190 (36.3)
Female sex, N (%) 17 (73.9) 80 (50.3) 288 (55.1) 0.1
Sample source (N, %)
 Hospital 19 (82.6) 131 (82.4) 453 (86.6) 0.39
 General practice 4 (17.4) 28 (17.6) 70 (13.4)
Median Elixhauser score (% with data available) 6.70 (56.5) 6.75 (57.2) Data not available 0.95
Descriptives
Hospital-onset episodes N/total with data available (%) 11/22 (50) 73/141 (51.8) 244/446 (52.3) 0.95
Toxin EIA positivea, N (%) 14/21 (63.6) 43/98 (43.9) 132/319 (41.3) 0.08
Speciality, N (%)
 Medicine 10 (43.5) 83 (52.2) 259 (49.5) 0.69
 Surgery 5 (21.7) 23 (14.5) 95 (18.2)
 General practice 4 (17.3) 28 (17.6) 70 (13.4)
 Other 4 (17.3) 25 (15.6) 99 (18.9)
Biomarkers, median (range)
CRP (mg/L) 173 (36–319) 44 (1–358) 99 (1–364) <0.008
Leukocytes (x109/L) 15.0 (6.5–22) 11.2 (2.5–30.3) 11.0 (0.3–51.4) 0.22
Albumin (g/L) 17.5 (11–24) 23 (12–36) 23 (11–48) 0.07
Creatinine (μmol/L) 98.5 (39–229) 80 (38–225) 68 (30–660) 0.36
Outcome
Length of hospital stay (days) in 30-day survivors, mean (±SD) 15.8 (±20.8) 20.2 (±21.9) 22.7 (±29.1) 0.74
Death within 30 days of sampling, N/total with data available (%) 7/17 (41.2) 23/105 (21.9) 60/341 (17.5) 0.02

CRP, C-reactive protein; EIA, enzyme immunoassay; SD, standard deviation.

Data were compared between episodes caused by different ribotypes: RT220, RT002 with RT015, and all other ribotypes.

a

Toxin EIA testing undertaken from July 2012.

b

Chi-squared test for categorical variables.